Valeant Ad Hoc Committee investigation over, no additional restatements required; shares up 13% premarket

|By:, SA News Editor

Valeant Pharmaceuticals (NYSE:VRX) is up 13% premarket on robust volume in response to its announcement that the board's Ad Hoc Committee has completed its inquiry into Philidor and related accounting matters. No additional items were identified that would necessitate a restatement beyond those already disclosed.

As previously disclosed, the company is in the process of restating some of its financial statements. It expects to file its 2015 10-K no later than April 29.

Read now More Reasons That Valeant Stock May Be Worthless 

Subscribe for full text news in your inbox